Special Report: Guide To Next Week’s WHO Board Meeting – Budget, Medicines Access, Antimicrobial Resistance, NCDs, More18/01/2019 By Catherine Saez, Intellectual Property Watch Leave a CommentThe World Health Organization Executive Board this month will consider an 8 percent WHO budget increase for 2020-2021, discuss environment health risks, the high price of cancer drugs, and how to facilitate access to medicines and vaccines. Also on the agenda is the fight against antimicrobial resistance, rising noncommunicable diseases, and tuberculosis. In another area, the Board is also expected to discuss its pandemic influenza framework, in particular access to influenza viruses under the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity. The Board will further be asked to consider new entities seeking to enter into official relationships with the WHO, and those with whom relations should be discontinued.
Sudden Vacancies At Some International Agencies, Industry Sees New Top Officials, Lawyers Engage In Firm-Hopping17/01/2019 By Catherine Saez, Intellectual Property Watch Leave a CommentWhile the World Bank Group and the United Nations Environment Programme (UNEP) are looking for new leaders following the unexpected resignations of their heads, the International Telecommunication Union re-elected its secretary general. The European Patent Office got two new vice-chairs, and the European Organization for Nuclear Research (CERN) a new president, both starting in January. Associations for the creative industry and the pharmaceutical industry also elected new top officials, and lawyers continued to practice firm-hopping.
European Council Advances SPC Waiver For Generics; Negotiations Coming16/01/2019 By David Branigan for Intellectual Property Watch Leave a CommentThe European Union Council of member states has approved a mandate for negotiations with the EU Parliament concerning a draft regulation aimed at boosting EU-based generic and biosimilar manufacturing for export by providing an exception to the extended intellectual property protection granted by special protection certificates (SPCs). The mandate brings the draft regulation a step closer to adoption, and it also suggests that Parliament’s recent amendments to the regulation are likely be key areas of debate in the negotiations, which are expected to begin in the coming weeks.
Supporting UHC And Better Explaining IP – The 2019 Pharma Industry Agenda16/01/2019 By Intellectual Property Watch Leave a Comment
Time To Put A Stop To The Abuse Of Orphan Drug Regulation- The Latest Scandal10/01/2019 By Intellectual Property Watch Leave a Comment
What’s The Cost Of Allowing Patent Theft? Don’t Wait To Find Out09/01/2019 By Intellectual Property Watch Leave a Comment
EIFL Looks Forward To An Exciting 2019 At WIPO20/12/2018 By Intellectual Property Watch Leave a Comment
Do Patent Trolls Exist? Two Studies Reach Different Conclusions (Part 2)18/12/2018 By Steven Seidenberg for Intellectual Property Watch 2 Comments
UNCTAD Finds Growth In Global Creative Economy Led By ‘New Breed’ Of Countries15/01/2019 By David Branigan for Intellectual Property Watch Leave a Comment
US IP Attachés: China’s IP Policy ‘Hijacked’ By Local Interests In 2018; Bad Faith Filings A ‘Cancer’21/12/2018 By William New, Intellectual Property Watch Leave a Comment
WHO Report Shows Global Progress On Influenza Preparedness Response18/12/2018 By David Branigan for Intellectual Property Watch Leave a Comment
WIPO Members Agree On Revision Of Draft Treaty On Protection of TK, Folklore17/12/2018 By Catherine Saez, Intellectual Property Watch Leave a Comment
EU Committees Amend SPC Manufacturing Waiver, Push Access To Generics, Biosimilars14/12/2018 By David Branigan for Intellectual Property Watch Leave a Comment
The Future Of The Ideas Business – The Rise Of Data-Driven Invention07/12/2018 By Intellectual Property Watch, Intellectual Property Watch 1 CommentNew ideas are getting harder to find, and with less ideas there is a decline in organisational productivity and economic growth. This isn’t new, nor is the fact that to counterbalance the decline in idea generation, research and development have received and continue to require heavy investment. But with daily news of innovation centres opening up across the globe, the question remains whether initiatives like open innovation, crowdsourcing, or simply putting more scientific brains together will do this investment justice. Last month, leading representatives of the IP, R&D and technology arenas met in Switzerland to discuss a technology-based alternative to human only idea generation. Hosted by data-driven invention company Iprova, the 2nd Data-Driven Invention Forum saw attendees from companies, such as Panasonic, Philips and DuPont as well as many other global organisations explore the future of innovation and the role data-driven invention plays in it. Here are some of the conclusions of the conference.
